Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Management Comments

Agilent Technologies (A) Reports Acquisition of ACEA Biosciences for $250M in CashSeptember 26, 2018 5:58 AM Cancer Genetics Enters Supply Agreement with Agilent TechnologiesSeptember 25, 2018 4:01 PM